Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 4/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.46 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31277017 | 1.00 | NOTUM (0.55) | NOTUMESR1ESR2ABHD6NAMPT | |
| SCHEMBL566389 | 0.87 | ESR1 (0.68) | NOTUMESR1ESR2ABHD6RIPK1 | |
| SCHEMBL30263783 | 0.87 | ESR1 (0.68) | NOTUMESR1ESR2ABHD6RIPK1 | |
| SCHEMBL26845990 | 0.86 | NOTUM (0.53) | NOTUMESR1ESR2ABHD6NAMPT | |
| SCHEMBL7786861 | 0.85 | ESR1 (0.53) | NOTUMESR1ESR2ABHD6NAMPT | |
| SCHEMBL5424954 | 0.84 | RIPK1 (0.72) | NOTUMESR1ESR2ABHD6RIPK1 | |
| SCHEMBL7524427 | 0.83 | ESR1 (0.44) | NOTUMESR1ESR2ABHD6NAMPT | |
| SCHEMBL25825897 | 0.81 | ABHD6 (0.47) | ESR1ESR2ABHD6HSP90AA1HSP90AB1 | |
| SCHEMBL506139 | 0.80 | ESR1 (0.59) | NOTUMESR1ESR2ABHD6RIPK1 | |
| SCHEMBL25604135 | 0.80 | ESR2 (0.77) | ESR1ESR2ABHD6HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2687507-B1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| EP-2687507-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| EP-2383259-A1 | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2069327-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008022979-A1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | NOTUM 4336/4885ESR1 2249/4885ESR2 1432/4885 |
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | LCAT, ACAT2, SOAT2 | NOTUM 223/4885ESR1 3324/4885ESR2 1745/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | NOTUM 4336/4885ESR1 2249/4885ESR2 1432/4885 |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | NOTUM 276/4885ESR1 3303/4885ESR2 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.